A phase 1, first-in-human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Kim Anna Reiss, Yuan Yuan, Naoto T. Ueno, Melissa Lynne Johnson, Saar Gill, Elizabeth Claire Dees, Joseph Chao, Mathew Angelos, Olga Shestova, Jonathan Stuart Serody, Saul Priceman, Debora Barton, Ramona F. Swaby, Amy Ronczka, Thomas Condamine, Daniel Cushing, Rehman Qureshi, Madison Kremp, Michael Klichinsky, Yara Abdou
Institutions: Abramson Cancer Center, University of Pennsylvania, City Of Hope National Medical Center, The University of Texas MD Anderson Cancer Center, Tennessee Oncology, UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Carisma Therapeutics (United States), Merck & Co., Inc., Rahway, NJ, USA (United States), Incyte (United States), Roswell Park Comprehensive Cancer Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4286295065